Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06594107
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-10
Brief Title:
Factors for the Onset and Course of Axial Spondylitis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Faktorer För Uppkomst Och Förlopp Av Axial Spondylartrit
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EISPA
Brief Summary:
In a research project investigators want to study the course of the disease of axial spondylitis the causes of disease onset prognosis and treatment effects The goal is to improve treatment and in the long run also prevention of the disease The project has a focus on the body39s own substance prostaglandin and its proinflammatory role in spondylitis but also other substances may be analyzed in blood and urine samples
The purpose of the research project is include newly diagnosed treatment-naive patients with axial spondyloarthritis to follow them after 1 and 2 years after treatment start to collect clinical data questionnaires blood and urinsamples to find blood or urine markers that can be used for precision therapy of axial spondylitis
The purpose of the research project is include newly diagnosed treatment-naive patients with axial spondyloarthritis to follow them after 1 and 2 years after treatment start to collect clinical data questionnaires blood and urinsamples to find blood or urine markers that can be used for precision therapy of axial spondylitis
Detailed Description:
The EISPA study is an epidemiological and translational study in axial spondylitis patients who are included in the Swedish Rheumatology Quality Register SRQ EISPA aims to include consecutive newly diagnosed axial spondylitis patients
Despite the fact that the disease is relatively common it takes on average 10 years after start of symptoms for patients be diagnosed with axial spondylitis
Axial spondylitis diagnosis is based on clinical findings rather than diagnostic tests which reflects lack of knowledge about what causes the disease At present our possibilities to predict the course of the disease and thereby individualize the care of the patient are limited Current treatment decreases inflammation rather than treating the cause of the disease
The first treatment step of axial spondylitis is with non-steroidal anti-inflammatory drugs or COX inhibitors which usually have insufficient effect against inflammatory pain and stiffness In addition these drugs are associated with side effects such as gastrointestinal and cardiovascular side effects Axial spondylitis is a multifactorial disease where the arachidonic acid cascade an increased prostaglandin production and release may play a major role With this there is a clear potential to develop new specific drugs to slow down the prostaglandin cascade in patients with axial spondylitis
Despite the fact that the disease is relatively common it takes on average 10 years after start of symptoms for patients be diagnosed with axial spondylitis
Axial spondylitis diagnosis is based on clinical findings rather than diagnostic tests which reflects lack of knowledge about what causes the disease At present our possibilities to predict the course of the disease and thereby individualize the care of the patient are limited Current treatment decreases inflammation rather than treating the cause of the disease
The first treatment step of axial spondylitis is with non-steroidal anti-inflammatory drugs or COX inhibitors which usually have insufficient effect against inflammatory pain and stiffness In addition these drugs are associated with side effects such as gastrointestinal and cardiovascular side effects Axial spondylitis is a multifactorial disease where the arachidonic acid cascade an increased prostaglandin production and release may play a major role With this there is a clear potential to develop new specific drugs to slow down the prostaglandin cascade in patients with axial spondylitis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None